Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: Superior efficacy of rituximab-based chemoimmunotherapy as an initial therapy in newly diagnosed patients with B cell indolent lymphomas: long-term results from a single center in China

Fig. 1

The comparison of outcomes between R-based chemoimmunotherapy and chemotherapy groups in 334 B-iNHLs patients. a Patients with R-based chemoimmunotherapy had superior PFS than patients with chemotherapy (110 vs. 49 months, P = 0.001). b Patients with R-based chemoimmunotherapy had superior OS than patients with chemotherapy (120 vs. 72 months, P < 0.001)

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us